Combination therapy with pegylated interferon plus ribavirin in the treatment of hepatitis C virus-related thrombocytopenia.

Creative Commons License

Karakan T., Cindoruk M., Degertekin B., Dogan İ. , Sancak A., Dumlu S., ...Daha Fazla

Current therapeutic research, clinical and experimental, cilt.66, sa.3, ss.247-53, 2005 (SCI Expanded İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 66 Konu: 3
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1016/j.curtheres.2005.06.002
  • Dergi Adı: Current therapeutic research, clinical and experimental
  • Sayfa Sayıları: ss.247-53


Background: Isolated thrombocytopenia is a common manifestation of hepatitis C virus (HCV) infection. There is no established treatment modality for this condition. The efficacy of standard interferon (IFN) monotherapy has been reported in some studies. The major disadvantage of this treatment is the high rate of recurrence due to viral breakthrough during the first 12 weeks of treatment. Pegylated IFNs are now the standard regimen for chronic hepatic disease due to HCV infection. However, due to a lack of evidence, pegylated IFNs are not widely used for HCV-related isolated thrombocytopenia.